Ignite Creation Date:
2024-05-05 @ 5:07 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00399477
Status:
COMPLETED
Last Update Posted:
2011-04-12
First Post:
2006-11-10
Brief Title:
A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinsons Disease
Sponsor:
Teva Neuroscience Inc
Organization:
Teva Branded Pharmaceutical Products RD Inc
Study Overview
Official Title:
Open-label Multicenter Effectiveness and Safety Study of Once Daily AZILECT as Mono- or Adjunct Therapy in Patients With Idiopathic Parkinsons Disease PD
Status:
COMPLETED
Status Verified Date:
2011-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients with Parkinsons Disease PD will be divided into 2 groups at each study center at their first visit based on the drugs they are taking for their PD
Group 1 Patients using Azilect and no other therapy
Group 2 Azilect in combination with other medications like Levodopa Mirapex or Requip
Group 1 Patients using Azilect and no other therapy
Group 2 Azilect in combination with other medications like Levodopa Mirapex or Requip
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None